Li Yan, president of Qilu Pharmaceuticals

The bioengineering and pharmaceutical industry in China is still in a catch-up phase, facing many barriers to break through, said Li Yan.

She suggested top-level design for the industry should be enhanced, where high-level policies supporting the development of the bioengineering and pharmaceutical industries should be rolled out as soon as possible, getting through every linkages including new drug project approval, reviewing, production and application. New research and development for global cutting-edge products should be encouraged. Industrial and supply chains of the industries should be strengthened in terms of stability and competitiveness.